Tier 3: Lipid Panel (Where Tesamorelin Shines)
Visceral fat reduction drives downstream lipid improvements. The metabolic phase III data from Stanley et al. showed tesamorelin-treated patients had meaningful improvements in triglycerides and cholesterol ratios, correlated with degree of visceral fat loss.
Triglycerides
What it measures: Fats circulating in the bloodstream, produced largely by the liver in response to carbohydrate intake and insulin resistance.
Why it matters for tesamorelin: Of all the lipid markers, triglycerides respond most directly to visceral fat reduction. Expect a 10-20% drop in triglycerides over a 12-26 week tesamorelin cycle if visceral fat is meaningfully reducing.
Target: Below 100 mg/dL. Triglycerides above 150 mg/dL at baseline are themselves a marker of visceral adiposity and are one reason to consider tesamorelin in the first place.
HDL and LDL Cholesterol
What they measure: HDL transports cholesterol back to the liver for disposal (protective). LDL delivers cholesterol to tissues — but each LDL particle carries one ApoB molecule, making LDL-C a reasonable proxy for atherogenic particle count.
Why it matters: Visceral fat loss tends to raise HDL and modestly lower LDL. If the lipid profile improves during your tesamorelin cycle, you have indirect evidence that visceral adipose tissue is shrinking — even without imaging.
Interpretation: A rising HDL with falling triglycerides is the signature metabolic response. If triglycerides climb instead of falling, either the dose is too low to drive meaningful lipolysis, or dietary compensation is overwhelming the effect.
Tier 4: Liver and Inflammation Safety
Tesamorelin has liver-reducing effects in NAFLD (Stanley 2019), but any compound that shifts hepatic metabolism warrants monitoring. hs-CRP tracks the systemic inflammatory drop that comes with visceral fat loss.
ALT (Liver Enzyme)
What it measures: Alanine aminotransferase — the most liver-specific of the common enzymes. Released when hepatocytes are injured.
Why it matters: In the Stanley et al. NAFLD trial, tesamorelin 2 mg daily for 12 months reduced liver fat and improved ALT. For most users, ALT should stay flat or trend down during a cycle. An upward drift above 40 U/L warrants pause and a recheck.
Optimal: Below 25 U/L. Standard labs call up to 40 U/L "normal," but that range was set using populations that included significant NAFLD. Optimal is below 25 for men and below 19 for women.
hs-CRP (High-Sensitivity C-Reactive Protein)
What it measures: Low-level systemic inflammation. CRP is produced by the liver in response to IL-6 and other inflammatory signals.
Why it matters for tesamorelin: Visceral fat is an endocrine organ that secretes inflammatory cytokines. As visceral fat shrinks, hs-CRP typically follows. A falling hs-CRP over a 12-26 week cycle is secondary evidence that the visceral fat reduction is happening.
Target: Below 1.0 mg/L. Baseline values above 3.0 mg/L indicate significant systemic inflammation — often associated with elevated visceral fat, which is itself a reason to consider tesamorelin.
Imaging: The Efficacy Gold Standard (Aspirational)
Bloodwork is a proxy for what matters most with tesamorelin: reduction in visceral adipose tissue (VAT). The Phase III endpoint was VAT measured by CT scan, showing an 18% reduction at 26 weeks.
CT or DEXA scan: The direct measurement of VAT. Typically $200-600 out of pocket depending on facility. If you are running tesamorelin for more than one cycle, a baseline and end-of-year VAT scan is worth budgeting for.
Cheaper proxies: Waist circumference (measure at the navel, not at the belt line) and waist-to-hip ratio correlate with VAT. Combined with the metabolic panel trends above, they give a reasonable picture without imaging.
For most self-funded users, bloodwork plus tape measure is the practical monitoring stack. Imaging is a bonus, not a requirement.
How to Order Labs
Three ways to get tesamorelin bloodwork done:
Direct-to-consumer labs: HealthLabs.com offers IGF-1, HbA1c, lipid panels, and metabolic panels without a prescription. Walk in to any LabCorp or Quest site. Results in 1-3 business days.
Primary care physician: IGF-1 is a standard endocrine test. If you have a cooperative doctor, most of this panel can be ordered under routine preventive care and may be covered by insurance.
Functional medicine practitioner: Best option if you want a full hormone workup (IGF-1 + IGFBP-3 + thyroid + cortisol) interpreted in context. Expect $150-400 for the office visit plus labs.
Budget-conscious stack: If you can only afford three tests, run IGF-1, fasting glucose, and a lipid panel. That covers the efficacy marker, the main safety marker, and the secondary efficacy signal for about $80-120 total direct-to-consumer.
Interpreting Results: What to Do With the Numbers
IGF-1 did not rise: Check reconstitution, storage, and injection technique. Tesamorelin is temperature-sensitive and loses potency fast if mishandled. If IGF-1 is flat at week 4 despite clean protocol, the vial may be inactive — switch lots or vendors before continuing.
IGF-1 climbed above 300 ng/mL: Reduce dose by 25-50%. For most users on 1 mg daily, dropping to 1 mg 5-on/2-off or 0.5 mg daily brings IGF-1 back into the upper-normal range without losing efficacy.
Fasting glucose rose 10+ mg/dL: Temporary GH-induced insulin resistance. If it persists past week 8 and HbA1c is trending up, reduce dose or cycle off. Adding metformin is an off-label option but addresses symptom, not cause.
Triglycerides rose instead of fell: Either the dose is too low to drive lipolysis, or dietary carbohydrate load is masking the effect. Reassess before blaming the peptide.
ALT rose above 40 U/L: Pause the protocol. Recheck in 2-4 weeks. ALT elevations on tesamorelin are uncommon in trial data — persistent elevation warrants a full hepatic workup.
When to Stop
These are bloodwork signals to discontinue tesamorelin:
IGF-1 above 400 ng/mL or above age-adjusted upper limit of normal (reduce dose first; stop if persistent)
Fasting glucose above 126 mg/dL on two consecutive measurements
HbA1c above 6.5%
ALT or AST above 3x the upper limit of normal
New-onset severe edema or carpal tunnel symptoms (GH-mediated, dose-dependent)
Any diagnosis of active malignancy — absolute contraindication per FDA label
Putting It All Together: Sample Protocol
Week -1 (Baseline): IGF-1, IGFBP-3, fasting glucose, HbA1c, full lipid panel, ALT, hs-CRP. Write the numbers down.
Week 4 (Early check): IGF-1 only. Must rise vs baseline. If flat, troubleshoot before continuing.
Week 12 (Mid-cycle): IGF-1, fasting glucose, ALT. Confirm safety markers stable, confirm IGF-1 in target range.
Week 24-26 (End of cycle): Full panel. Compare everything to baseline. Document:
IGF-1 delta (target: +50 to +150 ng/mL vs baseline)
Triglyceride delta (target: 10-20% drop)
HbA1c change (target: flat or down)
ALT (target: flat or down)
hs-CRP (target: down)
2-4 weeks post-cycle: Retest IGF-1. Confirms tesamorelin has cleared and IGF-1 has returned toward baseline — important if you are planning the next cycle or moving to a different GHRH analog.